Diagnosis and management of chronic myelomonocytic leukemia

Francesco Onida, Miloslav Beran

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chronic myelomonocytic leukemia is a heterogeneous hematologic malignancy classified among the mixed myelodysplastic/myeloproliferative diseases by the World Health Organization because of its myelodysplastic and myeloproliferative characteristics. In the proliferative form, diagnosis should include screening for known molecular abnormalities associated with constitutively active tyrosine kinases, which may be candidates for targeted therapies. Because patient life expectancy is highly variable and there is no consensus on optimal therapy, clinicians are advised to rely on a specific risk-oriented scoring system for clinical decision-making for individual patients. Although supportive care represents the milestone for disease management, novel active agents such as hypomethylating drugs recently have become available, so that the current therapeutic armamentarium now includes different treatment alternatives. Allogeneic stem cell transplantation may represent a curative option in highly selected patients.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalCurrent Hematologic Malignancy Reports
Volume3
Issue number1
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Leukemia, Myelomonocytic, Chronic
Myelodysplastic-Myeloproliferative Diseases
Stem Cell Transplantation
Hematologic Neoplasms
Therapeutics
Disease Management
Life Expectancy
Protein-Tyrosine Kinases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Diagnosis and management of chronic myelomonocytic leukemia. / Onida, Francesco; Beran, Miloslav.

In: Current Hematologic Malignancy Reports, Vol. 3, No. 1, 03.2008, p. 31-36.

Research output: Contribution to journalArticle

@article{c96d365093b849d2b9fd156d95a3053e,
title = "Diagnosis and management of chronic myelomonocytic leukemia",
abstract = "Chronic myelomonocytic leukemia is a heterogeneous hematologic malignancy classified among the mixed myelodysplastic/myeloproliferative diseases by the World Health Organization because of its myelodysplastic and myeloproliferative characteristics. In the proliferative form, diagnosis should include screening for known molecular abnormalities associated with constitutively active tyrosine kinases, which may be candidates for targeted therapies. Because patient life expectancy is highly variable and there is no consensus on optimal therapy, clinicians are advised to rely on a specific risk-oriented scoring system for clinical decision-making for individual patients. Although supportive care represents the milestone for disease management, novel active agents such as hypomethylating drugs recently have become available, so that the current therapeutic armamentarium now includes different treatment alternatives. Allogeneic stem cell transplantation may represent a curative option in highly selected patients.",
author = "Francesco Onida and Miloslav Beran",
year = "2008",
month = "3",
doi = "10.1007/s11899-008-0006-x",
language = "English",
volume = "3",
pages = "31--36",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Diagnosis and management of chronic myelomonocytic leukemia

AU - Onida, Francesco

AU - Beran, Miloslav

PY - 2008/3

Y1 - 2008/3

N2 - Chronic myelomonocytic leukemia is a heterogeneous hematologic malignancy classified among the mixed myelodysplastic/myeloproliferative diseases by the World Health Organization because of its myelodysplastic and myeloproliferative characteristics. In the proliferative form, diagnosis should include screening for known molecular abnormalities associated with constitutively active tyrosine kinases, which may be candidates for targeted therapies. Because patient life expectancy is highly variable and there is no consensus on optimal therapy, clinicians are advised to rely on a specific risk-oriented scoring system for clinical decision-making for individual patients. Although supportive care represents the milestone for disease management, novel active agents such as hypomethylating drugs recently have become available, so that the current therapeutic armamentarium now includes different treatment alternatives. Allogeneic stem cell transplantation may represent a curative option in highly selected patients.

AB - Chronic myelomonocytic leukemia is a heterogeneous hematologic malignancy classified among the mixed myelodysplastic/myeloproliferative diseases by the World Health Organization because of its myelodysplastic and myeloproliferative characteristics. In the proliferative form, diagnosis should include screening for known molecular abnormalities associated with constitutively active tyrosine kinases, which may be candidates for targeted therapies. Because patient life expectancy is highly variable and there is no consensus on optimal therapy, clinicians are advised to rely on a specific risk-oriented scoring system for clinical decision-making for individual patients. Although supportive care represents the milestone for disease management, novel active agents such as hypomethylating drugs recently have become available, so that the current therapeutic armamentarium now includes different treatment alternatives. Allogeneic stem cell transplantation may represent a curative option in highly selected patients.

UR - http://www.scopus.com/inward/record.url?scp=41849134682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849134682&partnerID=8YFLogxK

U2 - 10.1007/s11899-008-0006-x

DO - 10.1007/s11899-008-0006-x

M3 - Article

VL - 3

SP - 31

EP - 36

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 1

ER -